# US 2006/0154896 A1 · Phosphorylated dextrans

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154896 A1
- Document ID: US20060154896A1
- Status: Published application
- Kind: A1
- Application number: 10/522,047
- Filed: 2003-07-23
- Published: 2006-07-13
- Earliest claimed: 2002-07-23
- Inventors: Tadao Saito; Haruki Kitazawa
- Web page: https://patentgrep.com/patent/US20060154896A1

## CPC

- C08B 37/0021: {Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran}
- A61K 31/721: Dextrans
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 27/14: Decongestants or antiallergics
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Dextrans, which have no immunoreactivity, were revealed to exert immunopotentiating activities on their chemical phosphorylation. Since phosphorylated dextrans not only function as B cell mitogens, but also activate dendritic cells and induce IL-10 and IFN-γ, they can be expected to have effects in preventing infectious diseases and colitis, and in preventing allergic diseases by maintaining the Th1/Th2 balance.

## Claims

### Claim 1

An agent comprising a phosphorylated dextran as an active ingredient, and having an immunopotentiating activity.

### Claim 2 (depends on 1)

The agent of claim 1, wherein the agent is a B cell-specific mitogen.

### Claim 3 (depends on 1)

The agent of claim 1, wherein the immunopotentiating activity is a blastogenic activity.

### Claim 4 (depends on 1)

The agent of claim 1, wherein the immunopotentiating activity is an activity of inducing interferon γ (IFN-γ) or interleukin 10 (IL-10).

### Claim 5

A pharmaceutical composition for preventing, improving, or treating infectious diseases, colitis, or allergic diseases, wherein the composition comprises a phosphorylated dextran as an active ingredient.

### Claim 6

A food composition for preventing or improving infectious diseases, colitis, or allergic diseases, wherein the composition comprises a phosphorylated dextran as an active ingredient.

### Claim 7

A method for immunopotentiating a cell, which comprises the step of contacting the cell with a phosphorylated dextran.

### Claim 8 (depends on 7)

The method of claim 7, wherein the immunopotentiation is blastogenesis.

### Claim 9 (depends on 7)

The method of claim 7, wherein the immunopotentiation is the induction of interferon γ (IFN-γ) or interleukin 10 (IL-10).

### Claim 10 (depends on 7)

The method of claim 7, wherein the cells are derived from spleen cells or dendritic cells.

### Claim 11

A method for producing a phosphorylated dextran, which comprises the step of reacting a dextran with polyphosphoric acid in a formaldehyde solution.

### Claim 12 (depends on 11)

The method of claim 11, wherein a dextran and polyphosphoric acid are reacted under heat.

### Claim 13 (depends on 5)

The composition of claim 5, wherein the phosphorylated dextran is produced by a method comprising the following steps of:
(a) reacting a dextran with a phosphate buffer under heat;
(b) freeze-drying the reaction solution of step (a); and
(c) heating the freeze-dried sample of step (b) at 100-160° C. for 24 hours.

### Claim 14 (depends on 6)

The composition of claim 6, wherein the phosphorylated dextran is produced by a method comprising the following steps of:
(a) reacting a dextran with a phosphate buffer under heat;
(b) freeze-drying the reaction solution of step (a); and
(c) heating the freeze-dried sample of step (b) at 100-160° C. for 24 hours.

### Claim 15 (depends on 8)

The method of claim 8, wherein the cells are derived from spleen cells or dendritic cells.

### Claim 16 (depends on 9)

The method of claim 9, wherein the cells are derived from spleen cells or dendritic cells.
